The estimated Net Worth of Martin E Cearnal is at least $704 Tisíc dollars as of 1 December 2021. Mr. Cearnal owns over 2,114 units of Cumberland Pharmaceuticals stock worth over $240,956 and over the last 15 years he sold CPIX stock worth over $0. In addition, he makes $462,644 as Executive Vice President, Chief Commercial Officer a Director at Cumberland Pharmaceuticals.
Martin has made over 9 trades of the Cumberland Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 2,114 units of CPIX stock worth $9,576 on 1 December 2021.
The largest trade he's ever made was buying 12,985 units of Cumberland Pharmaceuticals stock on 17 March 2021 worth over $36,488. On average, Martin trades about 1,425 units every 155 days since 2010. As of 1 December 2021 he still owns at least 178,473 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Mr. Cearnal stock trades at the bottom of the page.
Martin E. Cearnal is Executive Vice President, Chief Commercial Officer,and Director of the Company. Mr. Cearnal has served as a member of our Board of Directors since 2004. In 2008, he joined our management team to head commercial development for Cumberland, currently serving as Executive Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000, and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has 50 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University. The Board believes Mr. Cearnal brings significant marketing-related knowledge to the Company, which has and will help facilitate successful product launches and marketing plans, among other contributions.
As the Executive Vice President, Chief Commercial Officer a Director of Cumberland Pharmaceuticals, the total compensation of Martin Cearnal at Cumberland Pharmaceuticals is $462,644. There are 4 executives at Cumberland Pharmaceuticals getting paid more, with A. Kazimi having the highest compensation of $1,477,300.
Martin Cearnal is 75, he's been the Executive Vice President, Chief Commercial Officer a Director of Cumberland Pharmaceuticals since 2017. There are 2 older and 17 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
Martin's mailing address filed with the SEC is 2525 WEST END AVE., SUITE 950, NASHVILLE, TN, 37203.
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv a Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include: